La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

ImmuCell Bilan de santé

Santé financière contrôle des critères 2/6

ImmuCell possède un total de capitaux propres de $23.5M et une dette totale de $11.3M, ce qui porte son ratio d'endettement à 48%. Son actif total et son passif total sont $41.9M et de $18.4M.

Informations clés

48.0%

Ratio d'endettement

US$11.26m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$1.32m
Fonds propres	US$23.46m
Total du passif	US$18.40m
Total des actifs	US$41.86m

Mises à jour récentes de la santé financière

Recent updates

Revenues Working Against ImmuCell Corporation's (NASDAQ:ICCC) Share Price

Aug 07

ImmuCell (NASDAQ:ICCC) Is Making Moderate Use Of Debt

Aug 10

Insufficient Growth At ImmuCell Corporation (NASDAQ:ICCC) Hampers Share Price

May 27

ImmuCell GAAP EPS of -$0.09, revenue of $3.86M

Aug 11

ImmuCell announces preliminary 2Q sales of $3.9M

Jul 07

Health Check: How Prudently Does ImmuCell (NASDAQ:ICCC) Use Debt?

Sep 15

Why We Think Shareholders May Be Considering Bumping Up ImmuCell Corporation's (NASDAQ:ICCC) CEO Compensation

Jun 10

Is ImmuCell (NASDAQ:ICCC) Using Too Much Debt?

Mar 15

Does ImmuCell's (NASDAQ:ICCC) Share Price Gain of 38% Match Its Business Performance?

Jan 22

ImmuCell reports FY20 preliminary sales

Jan 07

ImmuCell restructures its bank debt

Dec 15

ImmuCell EPS beats by $0.04, beats on revenue

Nov 12

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de ICCC ( $10.8M ) dépassent ses passifs à court terme ( $4.6M ).

Passif à long terme: Les actifs à court terme de ICCC ( $10.8M ) ne couvrent pas ses passifs à long terme ( $13.8M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de ICCC ( 42.4% ) est considéré comme élevé.

Réduire la dette: Le ratio d'endettement de ICCC est passé de 30% à 48% au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: ICCC dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: ICCC dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 8.2 % chaque année

ImmuCell Bilan de santé

Santé financière contrôle des critères 2/6

Informations clés

Mises à jour récentes de la santé financière

ImmuCell (NASDAQ:ICCC) Is Making Moderate Use Of Debt

ImmuCell Corporation announced delayed 10-Q filing

Health Check: How Prudently Does ImmuCell (NASDAQ:ICCC) Use Debt?

Is ImmuCell (NASDAQ:ICCC) Using Too Much Debt?

Recent updates

Second quarter 2024 earnings released: US$0.20 loss per share (vs US$0.18 loss in 2Q 2023)

New major risk - Financial position

ImmuCell Corporation to Report Q2, 2024 Results on Aug 13, 2024

Revenues Working Against ImmuCell Corporation's (NASDAQ:ICCC) Share Price

ImmuCell Corporation Provides Update on Regulatory Status of Product Development Initiative for Re-Tain®

First quarter 2024 earnings released: US$0.056 loss per share (vs US$0.30 loss in 1Q 2023)

ImmuCell Corporation to Report Q1, 2024 Results on May 14, 2024

ImmuCell Corporation, Annual General Meeting, Jun 13, 2024

ImmuCell Corporation has filed a Follow-on Equity Offering in the amount of $11 million.

ImmuCell Corporation has filed a Follow-on Equity Offering in the amount of $11 million.

Full year 2023 earnings released: US$0.74 loss per share (vs US$0.32 loss in FY 2022)

ImmuCell Corporation to Report Q4, 2023 Results on Feb 27, 2024

Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.085 loss in 3Q 2022)

Second quarter 2023 earnings released: US$0.18 loss per share (vs US$0.088 loss in 2Q 2022)

ImmuCell (NASDAQ:ICCC) Is Making Moderate Use Of Debt

ImmuCell Corporation to Report Q2, 2023 Results on Aug 10, 2023

Less than half of directors are independent

ImmuCell Corporation Appoints Bryan K. Gathagan to Board of Directors

Insufficient Growth At ImmuCell Corporation (NASDAQ:ICCC) Hampers Share Price

First quarter 2023 earnings released: US$0.30 loss per share (vs US$0.095 profit in 1Q 2022)

ImmuCell Corporation to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings released: US$322 loss per share (vs US$10.31 loss in FY 2021)

Full year 2022 earnings released: US$0.32 loss per share (vs US$0.01 loss in FY 2021)

ImmuCell Corporation to Report Fiscal Year 2022 Results on Feb 21, 2023

Insufficient new directors

David S. Cunningham Intends to Retire from the Board of Directors of David S. Cunningham

ImmuCell Corporation, Annual General Meeting, Jun 15, 2023

ImmuCell Corporation announced delayed 10-Q filing

Second quarter 2022 earnings released: US$0.088 loss per share (vs US$0.018 profit in 2Q 2021)

ImmuCell GAAP EPS of -$0.09, revenue of $3.86M

ImmuCell Corporation to Report Q2, 2022 Results on Aug 11, 2022

ImmuCell announces preliminary 2Q sales of $3.9M

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

ImmuCell Corporation to Report Q1, 2022 Results on May 12, 2022

Mark Wustenberg, DVM Joins Sales and Marketing Team as Commercial Leader of Stakeholder Engagement of ImmuCell Corporation

Insufficient new directors

Insufficient new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

ImmuCell Corporation to Report Q4, 2021 Results on Feb 22, 2022

Third quarter 2021 earnings released: EPS US$0.019 (vs US$0.045 loss in 3Q 2020)

Health Check: How Prudently Does ImmuCell (NASDAQ:ICCC) Use Debt?

Immucell Corporation Announces FDA Has Issued Technical Section Incomplete Letter Covering the Chemistry

Second quarter 2021 earnings released: EPS US$0.018 (vs US$0.11 loss in 2Q 2020)

Independent Director Jonathan Rothschild has left the company

Why We Think Shareholders May Be Considering Bumping Up ImmuCell Corporation's (NASDAQ:ICCC) CEO Compensation

First quarter 2021 earnings released: US$0.061 loss per share (vs US$0.017 loss in 1Q 2020)

Insider recently bought US$1.5m worth of stock

Full year 2020 earnings released: US$0.14 loss per share (vs US$0.19 loss in FY 2019)

Is ImmuCell (NASDAQ:ICCC) Using Too Much Debt?

Revenue beats expectations, earnings disappoint

Full year 2020 earnings released: US$0.14 loss per share (vs US$0.19 loss in FY 2019)

ImmuCell Corporation to Report Fiscal Year 2020 Results on Feb 22, 2021

New 90-day high: US$11.02

Does ImmuCell's (NASDAQ:ICCC) Share Price Gain of 38% Match Its Business Performance?

New 90-day high: US$6.65

ImmuCell reports FY20 preliminary sales

New 90-day high: US$6.42

ImmuCell restructures its bank debt

New 90-day high: US$6.23

Third quarter 2020 earnings released: US$0.045 loss per share

ImmuCell EPS beats by $0.04, beats on revenue

ImmuCell Corporation to Report Q3, 2020 Results on Nov 12, 2020

Earnings released

ImmuCell Corporation to Report Q2, 2020 Results on Aug 12, 2020

ImmuCell Corporation(NasdaqCM:ICCC) dropped from Russell Microcap Growth Index

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines